918 / 945
Summary (MR-only)
•
Main benefits
•
No registration
•
No need for the CT examination
•
Commercial solutions are now on the market
•
Only male pelvis (prostate)
•
There are promising solutions described also for intra-cranial tumors
•
Technical aspects
•
The dose calculation is insensitive and probably the least problem
•
Use for positioning is difficult to verify
•
Potential error sources and QA measures needs to be identified